• 1
    Franco EL, Ferenczy A. Chapter 16: cervix. In: FrancoEL, RohanTE, eds. Cancer precursors: epidemiology, detection and prevention. New York: Springer, 2002: 24986.
  • 2
    Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. JAMA 1994; 271: 18669.
  • 3
    Cox JT. HPV testing: is it useful in triage of minor Pap abnormalities? J Fam Pract 1998; 46: 1214.
  • 4
    Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, Wiener H, Herbert A, von Karsa L. European guidelines for quality assurance in cervical cancer screening. Second edition-summary document. Ann Oncol 2010; 21: 44858.
  • 5
    Robertson JH, Woodend BE, Crozier EH, Hutchinson J. Risk of cervical cancer associated with mild dyskaryosis. BMJ 1988; 297: 1821.
  • 6
    Flannelly G, Anderson D, Kitchener HC, Mann EM, Campbell M, Fisher P, Walker F, Templeton AA. Management of women with mild and moderate cervical dyskaryosis. BMJ 1994; 308: 1399403.
  • 7
    Richart RM, Wright TC, Jr. Controversies in the management of low-grade cervical intraepithelial neoplasia. Cancer 1993; 71: 141321.
  • 8
    Soutter WP. Management of women with mild dyskaryosis. Immediate referral to colposcopy is safer. BMJ 1994; 309: 5912.
  • 9
    Ferenczy A. Viral testing for genital human papillomavirus infections: recent progress and clinical potentials. Int J Gynecol Cancer 1995; 5: 3218.
  • 10
    Wilkinson C, Jones JM, McBride J. Anxiety caused by abnormal result of cervical smear test: a controlled trial. BMJ 1990; 300: 440.
  • 11
    Hellsten C, Sjöström K, Lindqvist PG. A 2-year follow-up study of anxiety and depression in women referred for colposcopy after an abnormal cervical smear. BJOG 2008; 115: 2128.
  • 12
    Östör AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993; 12: 18692.
  • 13
    Cox JT, Lörincz AT, Schiffman MH, Sherman ME, Cullen A, Kurman RJ. Human papillomavirus testing by hybrid capture appears useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 1995; 172: 94654.
  • 14
    Wright TC, Sun XW, Koulos J. Comparison of management algorithms for the evaluation of women with low-grade cytologic abnormalities. Obstet Gynecol 1995; 85: 20210.
  • 15
    Kinney WK, Manos MM, Hurley LB, Ransley JE. Where's the high-grade cervical neoplasia? The importance of minimally abnormal Papanicolaou diagnoses. Obstet Gynecol 1998; 91: 9736.
  • 16
    Andersson S, Dillner L, Elfgren K, Mints M, Persson M, Rylander E. A comparison of the human papillomavirus test and Papanicolaou smear as a second screening method for women with minor cytological abnormalities. Acta Obstet Gynecol Scand 2005; 84: 9961000.
  • 17
    Kaufman RH, Adam E. Does typing of human papillomavirus assist in the triage of women with repeated low-grade, cervical cytologic abnormalities? Gynecol Oncol 1998; 70: 3178.
  • 18
    Kaufman RH, Adam E. Is human papillomavirus testing of value in clinical practice? Am J Obstet Gynecol 1999; 180: 104953.
  • 19
    Cuzick J, Sasieni P, Davies P, Adams J, Normand C, Frater A, van Ballegooijen M, van den Akker E. A systematic review of the role of human papillomavirus testing within a cervical screening programme. Health Technol Assess 1999; 3: iiv, 1–196.
  • 20
    Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Dillner J. Clinical utility of HPV DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN. An update of pooled evidence. Gynecol Oncol 2005; 99( Suppl 3): 711.
  • 21
    ALTS (ASCUS-LSIL Triage Study) Group. Results of a randomised trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003; 188: 138392.
  • 22
    Solomon D, Papillo JL, Davey DD, on behalf of the Cytopathology Education and Technology Consortium. Statement on HPV DNA test utilization. Am J Pathol 2009; 131: 7689.
  • 23
    Jordan J, Arbyn M, Martin-Hirsch P, Schenck U, Baldauf J-J, Da Silva D, Anttila A, Nieminen P, Prendiville W. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part I. Cytopathology 2008; 19: 34254.
  • 24
    Scott DR, Hagmar B, Maddox P, Hjerpe A, Dillner J, Cuzick J, Sherman ME, Stoler MH, Kurman RJ, Kiviat NB, Manos MM, Schiffman M. Use of human papillomavirus DNA testing to compare equivocal cervical cytologic interpretations in the United States, Scandinavia, and the United Kingdom. Cancer 2002; 96: 1420.
  • 25
    Hakama M, Pukkala E, Heikkilä M, Kallio M. Effectiveness of the public health policy for breast cancer screening in Finland: population based cohort study. BMJ 1997; 314: 8647.
  • 26
    Kotaniemi-Talonen L, Nieminen P, Anttila A, Hakama M. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. Br J Cancer 2005; 93: 8627.
  • 27
    KossLG, ed. Diagnostic cytology and its histopathologic basis, 3rd ed., Philadelphia: Lippincott, 1979.
  • 28
    Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, Kurman RJ, Ransley JE, Fetterman ME, Hartinter JS, McIntosh KM, Pawlick GF, Hiat RA. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou test. JAMA 1999; 281: 160510.
  • 29
    Kerry SM, Bland JM. Trials which randomize practices II: sample size. Fam Pract 1998; 15: 847.
  • 30
    Klar N, Donner A. Current and future challenges in the design and analysis of cluster randomization trials. Stat Med 2001; 20: 372940.
  • 31
    Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol 2008; 111: 16777.
  • 32
    Strander B, Andersson-Ellström A, Milsom I, Rådberg T, Ryd W. Liquid-based cytology versus conventional Papanicolaou smear in an organized screening program: a prospective randomized study. Cancer 2007; 111: 28591.
  • 33
    Cotton S, Sharp L, Little J, Duncan I, Alexander L, Cruickshank M, Gray N, Jenkins D, Philips Z, Robertson A, Seth R, The TOMBOLA group. Trial of management of borderline and other low-grade abnormal smears (TOMBOLA): trial design. Contemp Clin Trials 2006; 27: 44971.